214 results on '"Puente V"'
Search Results
2. Healthcare education program in multiple system atrophy: Safety, quality and satisfaction from a national registry-based longitudinal study
- Author
-
Camara, A., primary, Compta, Y., additional, Baixauli, M., additional, Maragall, L., additional, Pérez-Soriano, A., additional, Montagut, N., additional, Ahuir, M., additional, Ludeña, E., additional, Peri, L., additional, Fernandez, N., additional, Villote, S., additional, Lopez de los Reyes, J.C., additional, Navarro-Otano, J., additional, Zaro, I., additional, Muñoz, E., additional, Buongiorno, M., additional, Caballol, N., additional, Pont-Sunyer, C., additional, Puente, V., additional, Giraldo, D.M., additional, Valldeoriola, F., additional, Lombraña, M., additional, and Marti, M.J., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
- Author
-
Santos-García, D., Catalán, M.J., Puente, V., Valldeoriola, F., Regidor, I., Mir, P., Matías-Arbelo, J., Parra, J.C., and Grandas, F.
- Published
- 2021
- Full Text
- View/download PDF
4. Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas
- Author
-
Santos-García, D., Catalán, M.J., Puente, V., Valldeoriola, F., Regidor, I., Mir, P., Matías-Arbelo, J., Parra, J.C., and Grandas, F.
- Published
- 2021
- Full Text
- View/download PDF
5. Corrigendum to “Pilot therapeutic education program in multiple system atrophy: Safety, quality of life and satisfaction from a national registry based longitudinal study” [Park. Relat. Disord. (2024) 106993]
- Author
-
Cámara, A., Compta, Y., Baixauli, M., Maragall, L., Pérez-Soriano, A., Montagut, N., Ahuir, M., Ludeña, E., Peri, L., Fernández, N., Villote, S., Lopez de los Reyes, J.C., Navarro - Otano, J., Zaro, I., Muñoz, E., Buongiorno, M., Caballol, N., Pont-Sunyer, C., Puente, V., Giraldo, D., Valldeoriola, F., Lombraña, M., and Martí, M.J.
- Published
- 2024
- Full Text
- View/download PDF
6. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort
- Author
-
Adarmes, A.D., Almeria, M., Alonso Losada, G., Alonso Cánovas, A., Alonso-Frech, F., Arribas, S., Ascunde Vidondo, A., Aquilar, M., Ávila, M.A., Bernardo Lambrich, N., Bejr-Kasem, H., Blázquez Estrada, M., Botí, M., Cabello González, C., Cabo López, I., Caballol, N., Cámara Lorenzo, A., Carrillo, F., Catalán, M.J., Clavero, P., Cortina Fernández, A., Crespo Cuevas, A., de Fábregues-Boixar, O., Díez-Fairen, M., Erro, E., Estelrich Peyret, E., Fernández Guillán, N., Gámez, P., Gallego, M., García Caldentey, J., García Campos, C., García Moreno, J.M., Gastón, I., Gómez Garre, M.P., González Aloy, J., González-Aramburu, I., González Ardura, J., González García, B., González Palmás, M.J., González Toledo, G.R., Golpe Díaz, A., Grau Solá, M., Guardia, G., Hernández-Vara, J., Horta Barba, A., Infante, J., Jesús, S., Kulisevsky, J., Kurtis, M., Labandeira, C., Labrador, M.A., Lacruz, F., Lage Castro, M., Legarda, I., López Ariztegui, N., López Díaz, L.M., López Manzanares, L., López Seoane, B., Martí Andres, G., Martí, M.J., Martínez-Castrillo, J.C., McAfee, D., Meitín, M.T., Menéndez González, M., Méndez del Barrio, C., Miranda Santiago, J., Morales Casado, M.I., Moreno Diéguez, A., Nogueira, V., Novo Amado, A., Novo Ponte, S., Ordás, C., Pagonabarraga, J., Pareés, I., Pascual-Sedano, B., Pastor, P., Pérez Fuertes, A., Pérez Noguera, R., Planellas, Ll, Pol Fuster, J., Prats, M.A., Prieto Jurczynska, C., Puente, V., Redondo Rafales, N., Rodríguez Méndez, L., Roldán, F., Ruíz De Arcos, M., Ruíz Martínez, J., Sánchez Alonso, P., Sánchez-Carpintero, M., Sánchez Díez, G., Sánchez Rodríguez, A., Santacruz, P., Segundo Rodríguez, J.C., Seijo, M., Serarols, A., Sierra Peña, M., Tartari, J.P., Vargas, L., Vázquez Gómez, R., Villanueva, C., Vives, B., Villar, M.D., Santos García, D., de Deus Fonticoba, T., Suárez Castro, E., Borrué, C., Mata, M., Solano Vila, B., Cots Foraster, A., Álvarez Sauco, M., Rodríguez Pérez, A.B., Vela, L., Macías, Y., Escalante, S., Esteve, P., Reverté Villarroya, S., Cubo, E., Casas, E., Arnaiz, S., Carrillo Padilla, F., Pueyo Morlans, M., Mir, P., and Martinez-Martin, P.
- Published
- 2019
- Full Text
- View/download PDF
7. Efecto de la suplementacion con niveles crecientes de probioticos sobre la histomorfometria del intestino delgado del cuy (Cavia porcellus)
- Author
-
Puente V., Jhosseline, Carcelén C., Fernando, Ara G., Miguel, Bezada Q., Sandra, Huamán C., Amparo, Santillán, Gilberto, Perales, Rosa, Guevara V., Jorge, and Asencios M., Ana
- Published
- 2019
- Full Text
- View/download PDF
8. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry
- Author
-
Amalia, Ene, Arnold, Guy, Bajenaru, Ovidiu, Bergmans, Bruno, Bjornara, Kari Anne, Blackie, Jeff, Bode, Matthias, Bourgeois, Paul, Bohlhalter, Stephan, Buraga, Ioan, Burkhard, Pierre R., Busson, Philippe, Calopa, Matilde, Clausen, Jesper, Danielsen, Erik Hvid, Defebvre, Luc, Delvaux, Valerie, Dethy, Sophie, Dietrichs, Espen, De Fabregues, Oriol, Gerhard, Ransmayr, Gusmaroli, Graziano, Hahn, Kirsten, Hauptmann, Björn, Henriksen, Tove, Hernandez-Vara, Jorge, Jeanjean, A., Kaiserova, Michaela, Kassubek, Jan, Kimber, Thomas, Konitsiotis, Spyridon, Krüger, Rejko, Kulisevsky, Jaime, Leenders, Jo, Lundqvist, Christofer, Ory Magne, F., Marano, Pietro, Milanov, Ivan, Modugno, Nicola, Misbahuddin, Anjum, Nevrly, Martin, Panayiotis, Zikos, Pedersen, Kenn Freddy, Pedersen, Stephen W., Perju-Dumbrava, Lacramioara, Ponsen, M.M., Popescu, Bogdan O., Rijntjes, Michel, Puente, V., Redecker, Christoph, Schrader, Christoph, Sensi, Mariachiara, Simu, Mihaela, Spanaki, Cleanthe, Storch, Alexander, Storstein, Anette, Tomantschger, Volker, van der Linden, Chris, van Laar, T., Viallet, F., Witjas, Tatiana, Wolz, Martin, Zibetti, Maurizio, Van Zandijcke, Michel, Antonini, Angelo, Poewe, Werner, Chaudhuri, K. Ray, Jech, Robert, Pickut, Barbara, Pirtošek, Zvezdan, Szasz, Jozsef, Valldeoriola, Francesc, Winkler, Christian, Bergmann, Lars, Yegin, Ashley, Onuk, Koray, Barch, David, and Odin, Per
- Published
- 2017
- Full Text
- View/download PDF
9. Advanced Parkinson's disease: Clinical characteristics and treatment. Part II
- Author
-
Kulisevsky, J., Luquin, M.R., Arbelo, J.M., Burguera, J.A., Carrillo, F., Castro, A., Chacón, J., García-Ruiz, P.J., Lezcano, E., Mir, P., Martinez-Castrillo, J.C., Martínez-Torres, I., Puente, V., Sesar, Á., Valldeoriola-Serra, F., and Yañez, R.
- Published
- 2013
- Full Text
- View/download PDF
10. Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II
- Author
-
Kulisevsky, J., Luquin, M.R., Arbelo, J.M., Burguera, J.A., Carrillo, F., Castro, A., Chacón, J., García-Ruiz, P.J., Lezcano, E., Mir, P., Martinez-Castrillo, J.C., Martínez-Torres, I., Puente, V., Sesar, Á., Valldeoriola-Serra, F., and Yañez, R.
- Published
- 2013
- Full Text
- View/download PDF
11. Load Unbalance in k-ary n-Cube Networks
- Author
-
Miguel-Alonso, J., Gregorio, J. A., Puente, V., Vallejo, F., Beivide, R., Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Danelutto, Marco, editor, Vanneschi, Marco, editor, and Laforenza, Domenico, editor
- Published
- 2004
- Full Text
- View/download PDF
12. Advanced Parkinson's disease: Clinical characteristics and treatment (part 1)
- Author
-
Kulisevsky, J., Luquin, M.R., Arbelo, J.M., Burguera, J.A., Carrillo, F., Castro, A., Chacón, J., García-Ruiz, P.J., Lezcano, E., Mir, P., Martinez-Castrillo, J.C., Martínez-Torres, I., Puente, V., Sesar, A., Valldeoriola-Serra, F., and Yañez, R.
- Published
- 2013
- Full Text
- View/download PDF
13. Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life
- Author
-
Santos García, Diego, Deus Fonticoba, María Teresa de, Paz González, J. M., Cores Bartolomé, C., Valdés Aymerich, L., Muñoz Enríquez, J. G., Suárez, E., Jesús, S., Aguilar Barberà, Miquel, Pastor, P., Planellas, L. L., Cosgaya, M., García Caldentey, J., Caballol, N., Legarda, I., Hernández-Vara, Jorge, Cabo, I., López Manzanares, L., González Aramburu, I., Ávila-Rivera, M. A, Catalán, M. J., Nogueira, V., Puente, V., García Moreno, José Manuel, Borrué, C., Solano Vila, B., Álvarez Sauco, M., Vela, Lydia, Escalante, S., Cubo, Esther, Carrillo Padilla, F., Martínez Castrillo, J. C., Sánchez Alonso, P., Alonso Losada, M. G., López Ariztegui, N., Gastón, I., Kulisevsky, Jaime, Blázquez Estrada, M., Seijo, M., Rúiz Martínez, J., Valero, C., Kurtis, M., Fàbregues-Boixar i Nebot, Oriol de, González Ardura, J., Ordás, C., López Díaz, L., Mir, P., Martinez-Martin, Pablo, COPPADIS Study Group, None, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Santos García D, Paz González JM, Cores Bartolomé C, Valdés Aymerich L, Muñoz Enríquez JG] CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. [De Deus Fonticoba T] CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain. [Hernández Vara J, de Fábregues O] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Universidad de Sevilla. Departamento de Medicina, [Santos Garcia, D.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Paz Gonzalez, J. M.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Cores Bartolome, C.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Valdes Aymerich, L.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [Munoz Enriquez, J. G.] Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain, [De Deus Fonticoba, T.] Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain, [Suarez, E.] Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain, [Jesus, S.] Univ Seville, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento, Hosp Univ Virgen Rocio,CSIC,Inst Biomed Sevilla, Seville, Spain, [Mir, P.] Univ Seville, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento, Hosp Univ Virgen Rocio,CSIC,Inst Biomed Sevilla, Seville, Spain, [Jesus, S.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Gonzalez Aramburu, I.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Kulisevsky, J.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Mir, P.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Martinez-Martin, P.] Ctr Invest Biomed Red Enfermedades Neurodegnerat, CIBERNED, Madrid, Spain, [Aguilar, M.] Hosp Univ Mutua Terrassa, Terrassa, Spain, [Pastor, P.] Hosp Univ Mutua Terrassa, Terrassa, Spain, [Planellas, L. L.] Hosp Clin Barcelona, Barcelona, Spain, [Cosgaya, M.] Hosp Clin Barcelona, Barcelona, Spain, [Garcia Caldentey, J.] Ctr Neurol Oms 42, Palma de Mallorca, Spain, [Caballol, N.] Hosp Moises Broggi, Consorci Sanitari Integral, Barcelona, Spain, [Legarda, I.] Hosp Univ Son Espases, Palma de Mallorca, Spain, [Hernandez Vara, J.] Hosp Univ Vall Hebron, Barcelona, Spain, [de Fabregues, O.] Hosp Univ Vall Hebron, Barcelona, Spain, [Cabo, I.] Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain, [Seijo, M.] Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain, [Lopez Manzanares, L.] Hosp Univ La Princesa, Madrid, Spain, [Gonzalez Aramburu, I.] Hosp Univ Marques Valdecilla, Santander, Spain, [Avila Rivera, M. A.] Hosp Gen Hosp, Consorci Sanitari Integral, Barcelona, Spain, [Catalan, M. J.] Hosp Univ Clin San Carlos, Madrid, Spain, [Nogueira, V.] Hosp Da Costa, Lugo, Spain, [Puente, V.] Hosp del Mar, Barcelona, Spain, [Garcia Moreno, J. M.] Hosp Univ Virgen Macarena, Seville, Spain, [Borrue, C.] Hosp Infanta Sofia, Madrid, Spain, [Solano Vila, B.] Inst Catala Salut, Inst Assistencia Sanitaria IAS, Girona, Spain, [Alvarez Sauco, M.] Hosp Gen Univ Elche, Elche, Spain, [Vela, L.] Fdn Hosp Alcorcon, Madrid, Spain, [Escalante, S.] Hosp Tortosa Verge Cinta IITVC, Tarragona, Spain, [Cubo, E.] Complejo Asistencial Univ Burgos, Burgos, Spain, [Carrillo Padilla, F.] Hosp Univ Canarias, San Cristobal De Laguna, Santa Cruz De T, Spain, [Martinez Castrillo, J. C.] Hosp Univ Ramon y Cajal, Madrid, Spain, [Sanchez Alonso, P.] Hosp Univ Puerta Hierro, Madrid, Spain, [Alonso Losada, M. G.] Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain, [Lopez Ariztegui, N.] Complejo Hosp Toledo, Toledo, Spain, [Gaston, I.] Complejo Hosp Navarra, Pamplona, Spain, [Kulisevsky, J.] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Blazquez Estrada, M.] Hosp Univ Cent Asturias, Oviedo, Spain, [Ruiz Martinez, J.] Hosp Univ Donostia, San Sebastian, Spain, [Valero, C.] Hosp Arnau Vilanova, Valencia, Spain, [Kurtis, M.] Hosp Ruber Int, Madrid, Spain, [Gonzalez Ardura, J.] Hosp Univ Lucus Augusti HULA, Lugo, Spain, [Ordas, C.] Hosp Rey Juan Carlos, Madrid, Spain, [Lopez Diaz, L.] Complejo Hosp Univ Orense CHUO, Orense, Spain, and [COPPADIS Study Grp] Fdn Curemos Parkinson, C Juana Vega 23 2, La Coruna 15004, Spain
- Subjects
medicine.medical_specialty ,Discapacitats ,Parkinson's disease ,Article Subject ,Degenerative Disorder ,Parkinson, Malaltia de - Prognosi ,Neuroscience (miscellaneous) ,Disease ,Stage ii ,personas::personas con discapacidad [DENOMINACIONES DE GRUPOS] ,Parkinson’s Disease ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades de los ganglios basales::trastornos parkinsonianos::enfermedad de Parkinson [ENFERMEDADES] ,Malaltia de Parkinson ,Internal medicine ,medicine ,Motor and nonmotor symptoms (NMS) ,Stage (cooking) ,RC346-429 ,030304 developmental biology ,ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD] ,Subtypes ,0303 health sciences ,Questionnaire ,business.industry ,Neurodegenerative disorder ,medicine.disease ,humanities ,Scale ,Psychiatry and Mental health ,Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE] ,Impact ,Persons::Disabled Persons [NAMED GROUPS] ,Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorders::Parkinson Disease [DISEASES] ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,Stage iv ,business ,030217 neurology & neurosurgery ,Qualitat de vida - Avaluació ,Research Article - Abstract
COPPADIS Study Group., [Introduction] In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient’s quality of life (QoL) with regard to a defined clinical stage., [Materials and Methods] Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0–20; B: NMSS = 21–40; C: NMSS = 41–70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale., [Results] A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (; e.g., PDQ-39SI in 1D [n = 15] vs 2A [n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; )., [Conclusion] The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.
- Published
- 2021
14. Impact of the Head-of-Line Blocking on Parallel Computer Networks: Hardware to Applications⋆
- Author
-
Puente, V., Gregorio, J. A., Beivide, R., Izu, C., Amestoy, Patrick, editor, Berger, Philippe, editor, Daydé, Michel, editor, Ruiz, Daniel, editor, Duff, Iain, editor, Frayssé, Valérie, editor, and Giraud, Luc, editor
- Published
- 1999
- Full Text
- View/download PDF
15. Risk of Cognitive Impairment in PD Patients with Visual Hallucinations and Subjective Cognitive Complaints
- Author
-
Garcia D, Fonticoba T, Painceiras M, Rios L, Roca L, Miro C, Canfield H, Jesus S, Pastor P, Cosgaya M, Caldentey J, Caballol N, Legarda I, Vara J, Cabo I, Manzanares L, Aramburu I, Rivera M, Mayordomo V, Nogueira V, Puente V, Garcia-Soto J, Borrue C, Solano B, and Sauco M
- Published
- 2022
16. Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group
- Author
-
Santos García D, García Roca L, de Deus Fonticoba T, Cores Bartolomé C, Naya Ríos L, Canfield H, Paz González JM, Martínez Miró C, Jesús S, Aguilar M, Pastor P, Planellas L, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Gómez Mayordomo V, Nogueira V, Puente V, Dotor García-Soto J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Blázquez Estrada M, Seijo M, Rúiz Martínez J, Valero C, Kurtis M, de Fábregues O, González Ardura J, Alonso Redondo R, Ordás C, López Díaz L LM, McAfee D, Martinez-Martin P, Mir P, and COPPADIS Study Group
- Subjects
impairment ,Cognition ,Parkinson's disease ,constipation ,non-motor symptoms - Abstract
Background: Constipation has been linked to cognitive impairment development in Parkinson's disease (PD). Objective: Our aim was to analyze cognitive changes observed in PD patients and controls from a Spanish cohort with regards to the presence or not of constipation. Methods: PD patients and controls recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017 were followed-up during 2 years. The change in cognitive status from baseline (V0) to 2-year follow-up was assessed with the PD-CRS (Parkinson's Disease Cognitive Rating Scale). Subjects with a score >= 1 on item 21 of the NMSS (Non-Motor Symptoms Scale) at baseline (V0) were considered as "with constipation". Regression analyses were applied for determining the contribution of constipation in cognitive changes. Results: At V0, 39.7% (198/499) of PD patients presented constipation compared to 11.4% of controls (14/123) (p < 0.0001). No change was observed in cognitive status (PD-CRS total score) neither in controls without constipation (from 100.24 +/- 13.72 to 100.27 +/- 13.68; p = 0.971) and with constipation (from 94.71 +/- 10.96 to 93.93 +/- 13.03; p = 0.615). The PD-CRS total score decreased significantly in PD patients with constipation (from 89.14 +/- 15.36 to 85.97 +/- 18.09; p
- Published
- 2022
17. Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up
- Author
-
Garcia D, Rios L, Fonticoba T, Bartolome C, Roca L, Painceiras M, Miro C, Canfield H, Jesus S, Aguilar M, Pastor P, Cosgaya M, Caldentey J, Caballol N, Legarda I, Vara J, Cabo I, Manzanares L, Aramburu I, Rivera M, Mayordomo V, Nogueira V, Puente V, Dotor J, Borrue C, Vila B, Sauco M, Vela L, Escalante S, Cubo E, Padilla F, Castrillo J, Alonso P, Losada M, Ariztegui N, Gaston I, Kulisevsky J, Estrada M, Seijo M, Martinez J, Valero C, Kurtis M, de Fabregues O, Ardura J, Redondo R, Ordas C, Diaz L, McAfee D, Martinez-Martin P, Mir P, COPPADIS Study Grp, Instituto de Salud Carlos III, Takeda Pharmaceutical Company, International Parkinson and Movement Disorder Society, AbbVie Pharmaceuticals, Abbott Laboratories, Allergan Foundation, BIAL Foundation, Merz Pharma, UCB Pharma, Zambon, Ministerio de Economía y Competitividad (España), European Commission, Junta de Andalucía, Sociedad Andaluza de Neurología, Jacques and Gloria Gossweiler Foundation, Fundación Alicia Koplowitz, Fundación Mutua Madrileña, Institut Català de la Salut, [Santos-García D, Naya Rios L, Cores Bartolomé C, García Roca L, Feal Painceiras M, Martínez Miró C] Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain. [de Deus Fonticoba T, Canfield H] Complejo Hospitalario Universitario de Ferrol (CHUF), A Coruña, Spain. [Jesús S, Mir P] Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain. Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. [Aguilar M, Pastor P] Hospital Universitari Mutua de Terrassa, Terrassa , Spain. [Cosgaya M] Hospital Clínic de Barcelona, Barcelona, Spain. [García-Caldentey J] Centro Neurológico Oms, Palma de Mallorca, Spain. [Caballol N] Consorci Sanitari Integral, Hospital Moisés Broggi, Barcelona, Spain. [Legarda I] Hospital Universitari Son Espases, Palma de Mallorca, Spain. [Hernández-Vara J, de Fábregues O] Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Cabo López I, Seijo M] Complexo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain. [López Manzanares L] Hospital Universitario La Princesa, Madrid, Spain. [González Aramburu I] Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Ávila Rivera MA] Consorci Sanitari Integral, Hospital General de L'Hospitalet, L'Hospitalet de Llobregat, Spain. [Gómez-Mayordomo V] Hospital Universitario Clínico San Carlos, Madrid, Spain. [Nogueira V] Hospital Da Costa, Burela, Lugo, Spain. [Puente V] Hospital del Mar, Barcelona, Spain. [Dotor J] Hospital Universitario Virgen Macarena, Sevilla, Spain. [Borrué C] Hospital Infanta Sofía, Madrid, Spain. [Solano Vila B] Institut d'Assistència Sanitària (IAS), Institut Català de la Salut (ICS), Salt, Spain. [Álvarez Sauco M] Hospital General Universitario de Elche, Elche, Spain. [Vela-Desojo L] Fundación Hospital de Alcorcón, Madrid, Spain. [Escalante S] Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Spain. [Cubo E] Complejo Asistencial Universitario de Burgos, Burgos, Spain. [Carrillo-Padilla F] Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Martínez Castrillo JC] Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain. [Sánchez Alonso P] Hospital Universitario Puerta de Hierro, Madrid, Spain. [Alonso Losada MG] Hospital Álvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain. [López-Ariztegui N] Complejo Hospitalario de Toledo, Toledo, Spain. [Gastón I] Complejo Hospitalario de Navarra, Pamplona, Spain. [Kulisevsky J] Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. Hospital de Sant Pau, Barcelona, Spain. [Blázquez Estrada M] Hospital Universitario Central de Asturias, Oviedo, Spain. [Ruiz-Martínez J] Hospital Universitario Donostia, San Sebastián, Spain. [Valero C] Hospital Arnau de Vilanova, València, Spain. [Kurtis M] Hospital Ruber Internacional, Madrid, Spain. [González Ardura J] Hospital de Cabueñes, Gijón, Spain. [Alonso Redondo R] Universitario Lucus Augusti (HULA), Lugo, Spain. [Ordás C] Hospital Rey Juan Carlos, Madrid, Spain. [López Díaz LM] Complexo Hospitalario Universitario de Ourense (CHUO), Ourense, Spain. [McAfee D] University of Maryland School of Medicine, Baltimore, USA. [Martinez-Martin P] Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, and Institut d'Assistència Sanitària
- Subjects
enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::trastornos del movimiento::trastornos parkinsonianos::enfermedades del sistema nervioso::enfermedad de Parkinson [ENFERMEDADES] ,Medicine (General) ,changes ,motor ,Parkinson’s disease ,phenotype ,PIGD ,Tremor ,endocrine system diseases ,genetic structures ,Parkinson's disease ,Clinical Biochemistry ,Tremolor ,Nervous System Diseases::Central Nervous System Diseases::Nervous System Diseases::Central Nervous System Diseases::Movement Disorders::Parkinsonian Disorders::Nervous System Diseases::Parkinson Disease [DISEASES] ,enfermedades del sistema nervioso::manifestaciones neurológicas::discinesias::temblor [ENFERMEDADES] ,Article ,eye diseases ,Fenotip ,R5-920 ,Genetic Phenomena::Phenotype [PHENOMENA AND PROCESSES] ,Parkinson, Malaltia de ,fenómenos genéticos::fenotipo [FENÓMENOS Y PROCESOS] ,Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Neurologic Manifestations::Dyskinesias::Tremor [DISEASES] - Abstract
[Background and objective] Diplopia is relatively common in Parkinson’s disease (PD) but is still understudied. Our aim was to analyze the frequency of diplopia in PD patients from a multicenter Spanish cohort, to compare the frequency with a control group, and to identify factors associated with it., [Patients and Methods] PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30 days follow-up (V2) from 35 centers of Spain from the COPPADIS cohort were included in this longitudinal prospective study. The patients and controls were classified as “with diplopia” or “without diplopia” according to item 15 of the Non-Motor Symptoms Scale (NMSS) at V0, V1 (1-year ± 15 days), and V2 for the patients and at V0 and V2 for the controls., [Results] The frequency of diplopia in the PD patients was 13.6% (94/691) at V0 (1.9% in controls [4/206]; p < 0.0001), 14.2% (86/604) at V1, and 17.1% (86/502) at V2 (0.8% in controls [1/124]; p < 0.0001), with a period prevalence of 24.9% (120/481). Visual hallucinations at any visit from V0 to V2 (OR = 2.264; 95%CI, 1.269–4.039; p = 0.006), a higher score on the NMSS at V0 (OR = 1.009; 95%CI, 1.012–1.024; p = 0.015), and a greater increase from V0 to V2 on the Unified Parkinson’s Disease Rating Scale–III (OR = 1.039; 95%CI, 1.023–1.083; p < 0.0001) and Neuropsychiatric Inventory (OR = 1.028; 95%CI, 1.001–1.057; p = 0.049) scores were independent factors associated with diplopia (R2 = 0.25; Hosmer and Lemeshow test, p = 0.716)., [Conclusions] Diplopia represents a frequent symptom in PD patients and is associated with motor and non-motor severity., Martínez-Martin P. has received honoraria from National School of Public Health (ISCIII), Editori-al Viguera and Takeda Pharmaceuticals for lecturing in courses, and from the International Parkinson and Movement Disorder Society (MDS) for management of the Program on Rating Scales. Mir P. has received honoraria from AbbVie, Abbott, Allergan, Bial, Merz, UCB, and Zambon and have received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575], co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [ PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña.
- Published
- 2021
18. Predictors of clinically significant quality of life impairment in Parkinson's disease
- Author
-
Garcia D, Fonticoba T, Cores C, Munoz G, Gonzalez J, Miro C, Suarez E, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey J, Caballol N, Legarda I, Vara J, Cabo I, Manzanares L, Aramburu I, Rivera M, Catalan M, Nogueira V, Puente V, de Arcos M, Borrue C, Vila B, Sauco M, Vela L, Escalante S, Cubo E, Padilla F, Castrillo J, Alonso P, Losada M, Ariztegui N, Gaston I, Clavero P, Kulisevsky J, Estrada M, Seijo M, Martinez J, Valero C, Kurtis M, de Fabregues O, Ardura J, Ordas C, Diaz L, McAfee D, Martinez-Martin P, Mir P, and COPPADIS Study Grp
- Abstract
Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months +/- 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 >= 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R-2 = 0.655). An increase in >= 5 and >= 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.
- Published
- 2021
19. Mood in Parkinson's disease: From early- to late-stage disease
- Author
-
Santos-Garcia D, De Deus F, Cores B, Valdes A, Suarez C, Aneiros A, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Garcia C, Caballol N, Legarda I, Hernandez V, Cabo I, Lopez M, Gonzalez A, Avila R, Jose C, Nogueira V, Puente V, Garcia M, Borrue C, Solano V, Alvarez S, Vela L, Escalante S, Cubo E, Carrillo P, Martinez C, Sanchez A, Alonso L, Lopez A, Gaston I, Kulisevsky J, Blazquez E, Seijo M, Ruiz M, Valero C, Kurtis M, de Fabregues-Boixar O, Prieto J, Lopez D, McAfee D, Mir P, and COPPADIS Study Grp
- Subjects
s disease ,quality of life ,mood ,depression ,disease duration ,Parkinson&apos ,Parkinson's disease - Abstract
BACKGROUND: Although depression is known to be frequent in Parkinson's disease (PD), it is unclear how mood can change and/or impact on patient's quality of life (QoL) over time. Our aim was to analyze the frequency of depression, mood related factors and the contribution of mood to a patient's QoL perception in regard to disease duration. METHODS: PD patients recruited from the COPPADIS cohort from January 2016 to November 2017 were included in this cross-sectional study. Three groups were defined
- Published
- 2021
20. Predictors of clinically significant quality of life impairment in Parkinson's disease
- Author
-
Santos García, Diego, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Muñoz, G., Paz González, J. M., Martínez Miró, C., Suárez, E., Jesús, S., Aguilar Barberà, Miquel, Pastor, P., Planellas, L., Cosgaya, Marina, García Caldentey, J., Caballol, Nuria, Legarda, I., Hernández-Vara, Jorge, Cabo-Lopez, Iria, López Manzanares, L., González Aramburu, I., Ávila, Asunción, Catalán, M. J., Nogueira, V., Puente, V., Ruíz de Arcos, M., Borrué, Carmen, Solano Vila, B., Álvarez Sauco, M., Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, Juan Carlos, Sánchez Alonso, P., Alonso Losada, M. G., López Ariztegui, N, Gastón, I., Clavero, P., Kulisevsky, Jaime, Blázquez Estrada, Marta, Seijo, M., Rúiz Martínez, J., Valero, C., Kurtis, M., Fàbregues-Boixar i Nebot, Oriol de, González-Ardura, J, Ordás, C., López Díaz, L. M., McAfee, D., Martinez-Martin, P., Mir, P., Adarmes, D. A., Almeria, Marta, Alonso-Cánovas, Araceli, Alonso Frech, Fernando, Alonso Redondo, Rubén, Álvarez, I., Aneiros Díaz, Á., Arnáiz, S., Arribas, S., Ascunce Vidondo, A., Bernardo Lambrich, N., Bejr-Kasem Marco, Helena, Botí, M. Ángeles, Buongiorno, M. T., Cabello González, C., Cámara, Ana, Canfield Medina, H., Carrillo, F., Casas, E., Cortina Fernández, A., Cots-Foraster, Anna, Crespo Cuevas, Ane Miren, Díez-Fairen, M., Dotor García-Soto, J., Erro, E., Estelrich Peyret, E., Fernández Guillán, N., Gámez, Pedro, Gallego, Miguel, García Campos, C., García Moreno, José Manuel, Gómez Garre, M. P., Gómez Mayordomo, V., González Aloy, J., González García, B., González Palmás, M. J., Toledo, G., Gabriel, R., Golpe Díaz, A., Grau Solá, M., Guardia, G., Horta, Andrea, Idoate Calderón, D., Infante, J., Labandeira, C., Labrador-Espinosa, Miguel A, Lacruz, F., Lage Castro, M., Lastres Gómez, S., López Seoane, B., Lucas del Pozo, S., Macías, Y., Mata, M., Martí Andres, G., Martí, M. J., Meitín, M. T., Menéndez González, M., Méndez del Barrio, C., Miranda Santiago, J., Casado, M., María, I., Moreno Diéguez, A., Novo Amado, A., Novo Ponte, S., Pagonabarraga Mora, Javier, Pareés, I., Pascual-Sedano, Berta María, Pérez Fuertes, A., Pérez Noguera, R., Planas-Ballvé, A., Prats, M. A., Prieto Jurczynska, C., Pueyo Morlans, M., Puig-Davi, Arnau, Redondo Rafales, N., Rodríguez Méndez, L., Rodríguez Pérez, A. B., Roldán, F., Sánchez-Carpintero, M., Sánchez Díez, G., Sánchez Rodríguez, A., Santacruz, P., Segundo Rodríguez, J. C., Sierra Peña, M., Tartari, J. P., Vargas, L., Villanueva, C., Vives-Pastor, B, Villar, M. D., Institut Català de la Salut, [Santos García D, Cores C, Muñoz G, Paz González JM, Martínez Miró C] CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. [de Deus Fonticoba T] CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain. [Hernández Vara J, de Fábregues O] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Universidad de Cantabria, AbbVie Pharmaceuticals, Abbott Laboratories, Allergan Foundation, BIAL Foundation, Merz Pharma, UCB Pharma, Zambon, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Junta de Andalucía, Sociedad Andaluza de Neurología, Jacques and Gloria Gossweiler Foundation, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña
- Subjects
Quality of life ,Qualitat de vida--Avaluació ,Parkinson's disease ,Parkinson, Malaltia de - Prognosi ,Nervous System Diseases::Nervous System Diseases::Nervous System Diseases::Neurodegenerative Diseases::Parkinson Disease [DISEASES] ,Article ,humanities ,Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE] ,Cellular and Molecular Neuroscience ,enfermedades del sistema nervioso::enfermedades del sistema nervioso::enfermedades del sistema nervioso::enfermedades neurodegenerativas::enfermedad de Parkinson [ENFERMEDADES] ,Neurology ,Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression::Clinical Deterioration [DISEASES] ,Neurology. Diseases of the nervous system ,Neurology (clinical) ,Parkinson, Malaltia de ,RC346-429 ,afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::progresión de la enfermedad::deterioro clínico [ENFERMEDADES] ,Qualitat de vida - Avaluació ,ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD] - Abstract
COPPADIS Study Group., Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p, Mir P. has received honoraria from AbbVie, Abbott, Allergan, Bial, Merz, UCB and Zambon and have received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña.
- Published
- 2021
21. Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas
- Author
-
Universidad de Sevilla. Departamento de Medicina, Santos-García, D., Catalán, M.J., Puente, V., Valldeoriola, F., Regidor, I., Mir Rivera, Pablo, Universidad de Sevilla. Departamento de Medicina, Santos-García, D., Catalán, M.J., Puente, V., Valldeoriola, F., Regidor, I., and Mir Rivera, Pablo
- Abstract
Objetivos: Comparar las características de los pacientes con enfermedad de Parkinson avan- zada en tratamiento con infusión intestinal continua de levodopa-carbidopa (IICLC) y los datos de efectividad y seguridad de IICLC entre diferentes comunidades autónomas (CC. AA.). Métodos: Estudio longitudinal observacional y retrospectivo. Se incluyeron 177 pacientes de 11 CC. AA. que iniciaron tratamiento con IICLC entre enero de 2006 y diciembre de 2011. Se compararon las características clínicas y demográficas, las variables de efectividad (cambios en el tiempo OFF, ON con y sin discinesias discapacitantes, cambios en la escala de Hoehn y Yahr y puntuación de la Unified Parkinson’s Disease Rating Scale, síntomas no motores e Impresión Clínica Global) y seguridad (acontecimientos adversos), y la tasa de suspensión de IICLC. Resultados: Se hallaron diferencias significativas entre las CC. AA. en diversas variables basa- les: duración de la enfermedad hasta el inicio de IICLC, tiempo OFF (34,9-59,7%) y ON (con o sin discinesias; 2,6-48,0%), Hoehn y Yahr en ON, Unified Parkinson’s Disease Rating Scale-III en ON y OFF, presencia de ≥ 4 síntomas motores y dosis de IICLC. En el seguimiento (> 24 meses en 9 de 11 CC. AA.) hubo diferencias significativas en el porcentaje de tiempo OFF, tiempo ON sin discinesias discapacitantes, frecuencia de acontecimientos adversos e Impresión Clínica Global. La tasa de suspensión fue de entre 20-40% en todas las CC. AA., excepto en 2 (78 y 80%). Conclusiones: Este estudio muestra una amplia variabilidad en la selección de los pacientes y en la efectividad y seguridad de IICLC entre las diferentes CC. AA. Podrían influir las caracterís- ticas basales de los pacientes, la disponibilidad de un equipo multidisciplinar y la experiencia clínica., Objectives: To compare the characteristics of patients undergoing treatment with continuous intestinal infusion of levodopa-carbidopa (CIILC) for advanced Parkinson’s disease and the data on the effectiveness and safety of CIILC in the different autonomous communities (AC) of Spain. Methods: A retrospective, longitudinal, observational study was carried out into 177 patients from 11 CAs who underwent CIILC between January 2006 and December 2011. We analysed data on patients’ clinical and demographic characteristics, variables related to effectiveness (chan- ges in off time/on time with or without disabling dyskinesia; changes in Hoehn and Yahr scale and Unified Parkinson’s Disease Rating Scale scores; non-motor symptoms; and Clinical Global Impression scale scores) and safety (adverse events), and the rate of CIILC discontinuation. Results: Significant differences were observed between CAs for several baseline variables: duration of disease progression prior to CIILC onset, off time (34.9-59.7%) and on time (2.6- 48.0%; with or without disabling dyskinesia), Hoehn and Yahr score during on time, Unified Parkinson’s Disease Rating Scale-III score during both on and off time, presence of ≥ 4 motor symptoms, and CIILC dose. Significant differences were observed during follow-up (> 24 months in 9 of the 11 CAs studied) for the percentage of off time and on time without disabling dys- kinesia, adverse events frequency, and Clinical Global Impression scores. The rate of CIILC discontinuation was between 20-40% in 9 CAs (78 and 80% in remaining 2 CAs). Conclusions: This study reveals a marked variability between CAs in terms of patient selection and CIILC safety and effectiveness. These results may have been influenced by patients’ baseline characteristics, the availability of multidisciplinary teams, and clinical experience.
- Published
- 2021
22. El uso de la lengua materna en interacciones orales en una lengua extranjera: un estudio de casos
- Author
-
Puente, V., Ruth, N., and Chacón, Carmen T.
- Published
- 2011
23. Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa
- Author
-
Kulisevsky, J, Bejr-Kasem, H, Martinez-Horta, S, Horta-Barba, A, Pascual-Sedano, B, Campolongo, A, Marin-Lahoz, J, Aracil-Bolanos, I, Perez-Perez, J, Izquierdo-Barrionuevo, C, de Fabregues, O, Puente, V, Crespo-Cuevas, A, Calopa, M, and Pagonabarraga, J
- Subjects
Levodopa ,carbidopa intestinal gel ,Executive function ,Parkinson's disease ,Mood ,Non-motor fluctuations ,Pharmacokinetics ,Anxiety - Abstract
Background Chronic levodopa treatment in Parkinson's disease (PD) may promote undesirable motor and non-motor fluctuations. Compared to chronic oral levodopa treatment, continuous infusion of levodopa/carbidopa intestinal gel (LCIG) in advanced PD reduces motor fluctuations. However, differences in their effect on acute non-motor changes were not formally demonstrated. Objective We performed a randomized, double-blind, double-dummy, crossover study to compare acute non-motor changes between intermittent oral immediate-release carbidopa/levodopa (LC-IR) and LCIG. Methods After > 12-h OFF, thirteen PD patients chronically treated with LCIG and without history of non-motor swings, were allocated to receive first, LCIG infusion plus three oral doses of placebo, or placebo infusion plus three oral doses of LC-IR. Over-encapsulated oral medication (LC-IR or placebo) was administered every 2 h. We monitored plasmatic levels of levodopa, motor status (UPDRS-III), mood, anxiety, and frontal functions at baseline (0-h) and hourly after each oral challenge. Results Repeated-measures ANOVAs showed significant group by treatment interaction indicating more fluctuations of levodopa plasma levels with LC-IR. No significant interactions were seen in the temporal profile of motor status, anxiety, mood and cognition. However, point-to-point parametric and nonparametric tests showed a significant more marked and more sustained improvement in anxiety scores under LCIG. A significant improvement of mood and verbal fluency was seen a + 3-h only under LCIG. Discussion Our sample of advanced PD patients exhibited moderate but significant non-motor fluctuations. LCIG was associated with a more favorable profile of acute affective and cognitive fluctuations that was particularly expressed at the first part of the infusion curve.
- Published
- 2020
24. High-performance adaptive routing for networks with arbitrary topology
- Author
-
Puente, V., Gregorio, J.A., Vallejo, F., Beivide, R., and Izu, C.
- Subjects
Network switch ,Network switches -- Analysis ,Computer science -- Analysis - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.sysarc.2005.09.003 Byline: V. Puente (a), J.A. Gregorio (a), F. Vallejo (a), R. Beivide (a), C. Izu (b) Keywords: Irregular topologies; Routing; Flow control; Deadlock; Cluster computing; Networks of workstations; Local area networks Abstract: A strategy to implement adaptive routing in irregular networks is presented and analyzed in this work. A simple and widely applicable deadlock avoidance method, applied to a ring embedded in the network topology, constitutes the basis of this high-performance packet switching. This adaptive router improves the network capabilities by allocating more resources to the fastest and most used virtual network, thus narrowing the performance gap with regular topologies. A thorough simulation process, which obtains statistically reliable measurements of irregular network behavior, has been carried out to evaluate it and compare with other state-of-the-art techniques. In all the experiments, our router exhibited the best behavior in terms of maximum/sustained performance and sensitivity to the network topology. Author Affiliation: (a) Computer Architecture Group, University of Cantabria, 39005 Santander, Spain (b) Computer Science Department, University of Adelaide, SA 50005, Australia
- Published
- 2006
25. Healthcare education program in multiple system atrophy - preliminary results of satisfaction from a national registry based longitudinal study
- Author
-
Cámara, A., primary, Compta, Y., additional, Pérez-Soriano, A., additional, Montagut, N., additional, Ahuir, M., additional, Ludeña, E., additional, Baixauli, M., additional, Peri-Cusi, L., additional, Fernández, N., additional, Villote, S., additional, Caballol, N., additional, Buongiorno, M., additional, Pont-Sunyer, C., additional, Puente, V., additional, Giraldo, D.M., additional, Garrido, A., additional, Painous, C., additional, Sánchez, A., additional, Muñoz, E., additional, Valldeoriola, F., additional, Lombraña, M., additional, and Martí, M.J., additional
- Published
- 2020
- Full Text
- View/download PDF
26. Effect of supplementation with increasing levels of probiotics on the histomorphometry of the small intestine of guinea pig (Cavia porcellus)
- Author
-
Puente V, Jhosseline, Carcelén C, Fernando, Ara G, Miguel, Bezada Q, Sandra, Huamán C, Amparo, Santillán, Gilberto, Perales, Rosa, Guevara V, Jorge, and Asencios M, Ana
- Subjects
histomorfometría intestinal ,probiótico ,cuy ,guinea pig ,probiotic ,gut histomorphometry - Abstract
El presente estudio evaluó el efecto de la suplementación con niveles crecientes de un probiótico líquido sobre la histomorfometría del intestino delgado en cuyes. Se utilizaron 50 cuyes machos a partir de los tres días de edad, distribuidos en un diseño completamente al azar de cinco tratamientos con diez repeticiones cada uno: 0, 1, 2 o 3 ml de probiótico o un antibiótico promotor del crecimiento (APC, Zn-Bacitracina). Se tomaron muestras de duodeno, yeyuno e íleon de cada animal a los 84 días de edad y se midió la longitud y ancho de las vellosidades intestinales, la profundidad de las criptas de Lieberkühn y la relación longitud/profundidad. No se evidenciaron patrones consistentes de respuesta para la mayoría de las mediciones en los tres segmentos, excepto una respuesta lineal (p=0.047) de la relación longitud/profundidad en el duodeno y un efecto positivo (p=0.008)del APC sobre la longitud de vellosidades en el íleon. Se concluye que, bajo las condiciones del estudio, los niveles del probiótico no provocaron un incremento en las dimensiones de las vellosidades y que, si lo hicieron, el efecto quedó enmascarado por una acelerada tasa de extrusión celular en las vellosidades. The present study evaluated the effect of supplementation with increasing levels of a liquid probiotic on the histomorphometry of the small intestine in guinea pigs. Fifty male guinea pigs were used from 3 days of age, distributed in a completely randomized design of five treatments with 10 repetitions each: 0, 1, 2 or 3 ml of probiotic or an antibiotic growth promoter (AGP, Zn-Bacitracin). Samples of duodenum, jejunum and ileum were taken from each animal at 84 days of age and the length and width of the intestinal villi, the depth of the Lieberkühn crypts and the length/depth relationship were measured. There were no consistent response patterns for most of the measurements in the three segments, except for a linear response (p=0.047) of the length/depth ratio in the duodenumanda positiveeffect (p=0.008)oftheAGPoverthe lengthofvilliinthe ileum. It is concluded that, under the conditions of the study, the levels of the probiotic did not cause an increase in the villus dimensions and if they did, the effect was masked by an accelerated rate of cell extrusion in the villi.
- Published
- 2019
27. alpha-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease
- Author
-
Garrido, A, Fairfoul, G, Tolosa, ES, Marti, MJ, Green, A, Compta, Y, Valldeoriola, F, Munoz, E, Fernandez, M, Alvarez, R, Vilas, D, Ispierto, L, De Fabregues, O, Hernandez-Vara, J, Puente, V, Calopa, M, Jauma, S, Campdelacreu, J, Bayes, A, Avila, A, Caballol, N, Aguilar, M, and Casquero, P
- Abstract
Background Leucine-rich kinase 2 (LRRK2)-linked Parkinson's disease (PD) is clinically indistinguishable from idiopathic PD (IPD). A pleiotropic neuropathology has been recognized but the majority of studies in LRRK2 p.G2019S patients reveal Lewy-type synucleinopathy as its principal histological substrate. To date no in vivo biomarkers of synucleinopathy have been found in LRRK2 mutation carriers. Objectives We used real-time quaking-induced conversion (RT-QuIC) technique to assess the presence of alpha-synuclein (a-syn) aggregates in cerebrospinal fluid (CSF) of LRRK2 p.G2019S carriers. Methods CSF samples of 51 subjects were analyzed: 15 LRRK2 p.G2019S PD, 10 IPD, 16 LRRK2 p.G2019S nonmanifesting carriers (NMC) and 10 healthy controls. The presence of parkinsonism and prodromal symptoms was assessed in all study subjects. Results Forty percent (n = 6) LRRK2-PD, and 18.8% (n = 3) LRRK2-NMC had a positive a-syn RT-QuIC response. RT-QuIC detected IPD with 90% sensitivity and 80% specificity. No clinical differences were detected between LRRK2-PD patients with positive and negative RT-QuIC. A positive RT-QuIC result in LRRK2-NMC occurred in a higher proportion of subjects meeting the Movement Disorder Society research criteria for prodromal PD. Interpretation RT-QuIC detects a-syn aggregation in CSF in a significant number of patients with LRRK2-PD, but less frequently than in IPD. A small percentage of LRRK2-NMC tested also positive. If appropriately validated in long-term studies with large number of mutation carriers, and hopefully, postmortem or in vivo confirmation of histopathology, RT-QuIC could contribute to the selection of candidates to receive disease modifying drugs, in particular treatments targeting a-syn deposition.
- Published
- 2019
28. High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients
- Author
-
Santos-Garcia, D, Fonticoba, TD, Castro, ES, Diaz, AA, Gonzalez, JMP, Panceiras, MJF, Sancho, CG, Jesus, S, Mir, P, Aguilar, M, Pastor, P, Vara, JH, de Fabregues-Boixar, O, Puente, V, Cuevas, AC, Gonzalez-Aramburu, I, Infante, J, Padilla, FC, Pueyo, M, Escalante, S, Bernardo, N, Solano, B, Foraster, AC, Martinez-Martin, P, Astrid, DA, Almeria, M, Losada, MGA, Canovas, AA, Frech, FA, Sauco, MA, Arnaiz, S, Arribas, S, Vidondo, AA, Avila, MA, Bejr-Kasem, H, Estrada, MB, Boti, M, Borrue, C, Gonzalez, CC, Lopez, IC, Caballol, N, Lorenzo, AC, Carrillo, F, Casas, E, Catalan, MJ, Clavero, P, Fernandez, AC, Cubo, E, Diez-Fairen, M, Erro, E, Peyret, EE, Guillan, NF, Gamez, P, Gallego, M, Caldentey, JG, Campos, CG, Moreno, JMG, Gaston, I, Garre, MPG, Aloy, JG, Ardura, JG, Garcia, BG, Palmas, MJG, Toledo, GRG, Diaz, AG, Sola, MG, Guardia, G, Horta-Barba, A, Kulisevsky, J, Kurtis, M, Labandeira, C, Labrador, MA, Lacruz, F, Castro, ML, Legarda, I, Ariztegui, NL, Diaz, LML, Manzanares, LL, Seoane, BL, Macias, Y, Mata, M, Andres, GM, Marti, MJ, Castrillo, JCM, McAfee, D, Meitin, MT, Gonzalez, MM, del Barrio, CM, Santiago, JM, Casado, MIM, Dieguez, AM, Nogueira, V, Amado, AN, Ponte, SN, Ordas, C, Pagonabarraga, J, Parees, I, Pascual-Sedano, B, Fuertes, AP, Noguera, RP, Planellas, L, Prats, MA, Jurczynska, CP, Rafales, NR, Mendez, LR, Perez, ABR, Roldan, F, De Arcos, MR, Martinez, JR, Alonso, PS, Sanchez-Carpintero, M, Diez, GS, Rodriguez, AS, Santacruz, P, Rodriguez, JCS, Seijo, M, Serarols, A, Pena, MS, Tartari, JP, Valero, C, Vargas, L, Gomez, RV, Vela, L, Villanueva, C, Vives, B, and Villar, MD
- Subjects
Inflammation ,genetic structures ,Parkinson's disease ,Freezing ,C-Reactive protein ,Gait - Abstract
C-reactive protein (CRP) is a biomarker of systemic inflammation that has been linked to accelerated decline in walking speed in older adults. The aim of the present study was to compare the CRP levels of PD patients with vs patients without freezing of gait (FOG). Patients and controls participating in the COPPADIS-2015 study that performed blood extraction for determining molecular serum biomarkers were included. Patients with FOG were identified as those with a score of 1 or greater on item-3 of the Freezing of Gait Questionnaire (FOG-Q). Immunoassay was used for determining ultrasensitive CRP (US-CRP) level (mg/dL). In the PD group (n = 225; 61.8 +/- 9.5 years old, 61.8% males), 32% of the patients presented FOG but none in the control group (n = 65; 60.3 +/- 6.1 years old, 56.9% males) (p < 0.0001). Differences in US-CRP level were significant in patients with FOG vs patients without FOG and vs controls (0.31 +/- 0.52 vs 0.16 +/- 0.21 vs 0.21 +/- 0.22; p = 0.04). Significant differences were also observed between patients with vs without FOG (p = 0.001) but not between patients and controls (p = 0.163). US-CRP level was related to FOG (OR = 4.369; 95% CI 1.105-17.275; p = 0.036) along with H&Y (OR = 2.974; 95% CI 1.113-7.943; p = 0.030) and non-motor symptoms burden (NMSS total score; OR = 1.017; 95% CI 1.005-1.029; p = 0.006) after adjusting for age, gender, disease duration, equivalent daily levodopa dose, number of non-antiparkinsonian drugs per day, motor fluctuations, cognition, motor phenotype, and chronic use of anti-inflammatory drugs. The present study suggests that serum US-CRP level is related to FOG in PD patients. Inflammation could be linked to FOG development.
- Published
- 2019
29. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation
- Author
-
Garcia, DS, Jesus, S, Aguilar, M, Planellas, LL, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Catalan, MJ, Diaz, LL, Puente, V, Moreno, JMG, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Padilla, FC, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gaston, I, Kulisevsky, J, Gonzalez, MM, Seijo, M, Martinez, JR, Valero, C, Kurtis, M, de Fabregues-Boixar, O, Ardura, JG, Jurczynska, CP, Martinez-Martin, P, Mir, P, Astrid, DA, Almeria, M, Canovas, AA, Frech, FA, Diaz, AA, Arnaiz, S, Arribas, S, Vidondo, AA, Lambrich, NB, Bejr-Kasem, H, Estrada, MB, Boti, M, Gonzalez, CC, Lorenzo, AC, Carrillo, F, Casas, E, Clavero, P, Fernandez, AC, Foraster, AC, Cuevas, AC, Fonticoba, TD, Diez-Fairen, M, Erro, E, Peyret, EE, Guillan, NF, Gamez, P, Gallego, M, Campos, CG, Garre, MPG, Aloy, JG, Garcia, BG, Palmas, MJG, Toledo, GRG, Diaz, AG, Sola, MG, Guardia, G, Horta-Barba, A, Infante, J, Labandeira, C, Labrador, MA, Lacruz, F, Castro, ML, Seoane, BL, Macias, Y, Mata, M, Andres, GM, Marti, MJ, McAfee, D, Meitin, MT, del Barrio, CM, Santiago, JM, Casado, MIM, Dieguez, AM, Nogueira, V, Amado, AN, Ponte, SN, Ordas, C, Pagonabarraga, J, Parees, I, Pascual-Sedano, B, Pastor, P, Fuertes, AP, Noguera, RP, Prats, MA, Morlans, MP, Rafales, NR, Mendez, LR, Perez, ABR, Roldan, F, De Arcos, MR, Sanchez-Carpintero, M, Diez, GS, Rodriguez, AS, Santacruz, P, Rodriguez, JCS, Serarols, A, Pena, MS, Castro, ES, Tartari, JP, Vargas, L, Gomez, RV, Villanueva, C, Vives, B, and Villar, MD
- Subjects
motor fluctuations ,quality of life ,mood ,Parkinson's disease ,gait ,non-motor symptoms - Abstract
Background and purpose In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well-designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS-2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015). Methods This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants. Results In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 +/- 8.9 years old, 60.3% males), 273 caregivers (58.5 +/- 11.9 years old, 31.8% males) and 207 controls (61 +/- 8.3 years old, 49.5% males). The mean disease duration was 5.5 +/- 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non-Motor Symptoms Scale total score was 45.4 +/- 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non-motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging). Conclusions Parkinson's disease is a complex disorder and different non-motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them.
- Published
- 2019
30. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort
- Author
-
Garcia, D, Fonticoba, T, Castro, E, Borrue, C, Mata, M, Vila, B, Foraster, A, Sauco, M, Perez, A, Vela, L, Macias, Y, Escalante, S, Esteve, P, Villarroya, S, Cubo, E, Casas, E, Arnaiz, S, Padilla, F, Morlans, M, Mir, P, Martinez-Martin, P, Adarmes, A, Almeria, M, Losada, G, Canovas, A, Alonso-Frech, F, Arribas, S, Vidondo, A, Aguilar, M, Avila, M, Lambrich, N, Bejr-Kasem, H, Estrada, M, Boti, M, Gonzalez, C, Lopez, I, Caballol, N, Lorenzo, A, Carrillo, F, Catalan, M, Clavero, P, Fernandez, A, Cuevas, A, de Fabregues-Boixar, O, Diez-Fairen, M, Erro, E, Peyret, E, Guinan, N, Gamez, P, Gallego, M, Caldentey, J, Campos, C, Moreno, J, Gaston, I, Garre, M, Aloy, J, Gonzalez-Aramburu, I, Ardura, J, Garcia, B, Palmas, M, Toledo, G, Diaz, A, Sola, M, Guardia, G, Hernandez-Vara, J, Barba, A, Infante, J, Jesus, S, Kulisevsky, J, Kurtis, M, Labandeira, C, Labrador, M, Lacruz, F, Castro, M, Legarda, I, Ariztegui, N, Diaz, L, Manzanares, L, Seoane, B, Andres, G, Marti, M, Martinez-Castrillo, J, McAfee, D, Meitin, M, Gonzalez, M, del Barrio, C, Santiago, J, Casado, M, Dieguez, A, Nogueira, V, Amado, A, Ponte, S, Ordas, C, Pagonabarraga, J, Parees, I, Pascual-Sedano, B, Pastor, P, Fuertes, A, Noguera, R, Planellas, L, Fuster, J, Prats, M, Jurczynska, C, Puente, V, Rafales, N, Mendez, L, Roldan, F, De Arcos, M, Martinez, J, Alonso, P, Sanchez-Carpintero, M, Diez, G, Rodriguez, A, Santacruz, P, Rodriguez, J, Seijo, M, Serarols, A, Pena, M, Tartari, J, Vargas, L, Gomez, R, Villanueva, C, Vives, B, Villar, M, and Coppadis Study Grp
- Subjects
Quality of life ,Parkinson's disease ,Mood ,Non-motor symptoms ,Gait ,humanities ,Motor fluctuations - Abstract
Objective: To identify factors related to a poor health-related and global quality of life (QoL) in a cohort of nondemented Parkinson's disease (PD) patients and compare to a control group. Methods: The data correspond to the baseline evaluation of the COPPADIS-2015 Study, an observational, 5-year follow-up, multicenter, evaluation study. Three instruments were used to assess QoL: (1) the 39-item Parkinson's disease Questionnaire (PDQ-39), (2) a subjective rating of global QoL (PQ-10), and (3) the EUROHIS-QOL 8-item index (EUROHIS-QOL8). Multiple linear regression methods were used to evaluate the direct impact of different variables on these QoL measures. Results: QoL was worse in PD patients (n = 692; 62.6 +/- 8.9 years old, 60.3% males) than controls (n = 206; 61 +/- 8.3 years old, 49.5% males): PDQ-39, 17.1 +/- 13.5 vs 4.4 +/- 6.3 (p < 0.0001); PQ-10, 7.3 +/- 1.6 vs 8.1 +/- 1.2 (p < 0.0001); EUROHIS-Q0L8, 3.8 +/- 0.6 vs 4.2 +/- 0.5 (p < 0.0001). A high correlation was observed between PDQ-39 and Non-Motor Symptoms Scale (NMSS) (r = 0.72; p < 0.0001), and PDQ-39 and Beck Depression Inventory-II (BDI-II) (r = 0.65; p < 0.0001). For health-related QoL (PDQ-39), non-motor symptoms burden (NMSS), mood (BDI-II), and gait problems (Freezing Of Gait Questionnaire [FOGQ]) provided the highest contribution to the model (beta = 0.32, 0.28, and 0.27, respectively; p < 0.0001); whereas mood and gait pro- blems contributed the most to global QoL (PQ-10, beta = -0.46 and -0.21, respectively; EUROHIS-QOL8, beta = - 0.44 and - 0.23, respectively). Conclusions: QoL is worse in PD patients than in controls. Mood, non-motor symptoms burden, and gait problems seem to be the most relevant factors affecting health-related and global perceived QoL in non-demented PD patients.
- Published
- 2019
31. Valproate-induced hyperammonemic encephalopathy
- Author
-
Segura-Bruna, N., Rodriguez-Campello, A., Puente, V., and Roquer, J.
- Published
- 2006
32. Impact of the Head-of-Line Blocking on Parallel Computer Networks: Hardware to Applications⋆
- Author
-
Puente, V., primary, Gregorio, J. A., additional, Beivide, R., additional, and Izu, C., additional
- Published
- 1999
- Full Text
- View/download PDF
33. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort
- Author
-
Santos García, D., primary, de Deus Fonticoba, T., additional, Suárez Castro, E., additional, Borrué, C., additional, Mata, M., additional, Solano Vila, B., additional, Cots Foraster, A., additional, Álvarez Sauco, M., additional, Rodríguez Pérez, A.B., additional, Vela, L., additional, Macías, Y., additional, Escalante, S., additional, Esteve, P., additional, Reverté Villarroya, S., additional, Cubo, E., additional, Casas, E., additional, Arnaiz, S., additional, Carrillo Padilla, F., additional, Pueyo Morlans, M., additional, Mir, P., additional, Martinez-Martin, P., additional, Adarmes, A.D., additional, Almeria, M., additional, Alonso Losada, G., additional, Alonso Cánovas, A., additional, Alonso-Frech, F., additional, Arribas, S., additional, Ascunde Vidondo, A., additional, Aquilar, M., additional, Ávila, M.A., additional, Bernardo Lambrich, N., additional, Bejr-Kasem, H., additional, Blázquez Estrada, M., additional, Botí, M., additional, Cabello González, C., additional, Cabo López, I., additional, Caballol, N., additional, Cámara Lorenzo, A., additional, Carrillo, F., additional, Catalán, M.J., additional, Clavero, P., additional, Cortina Fernández, A., additional, Crespo Cuevas, A., additional, de Fábregues-Boixar, O., additional, Díez-Fairen, M., additional, Erro, E., additional, Estelrich Peyret, E., additional, Fernández Guillán, N., additional, Gámez, P., additional, Gallego, M., additional, García Caldentey, J., additional, García Campos, C., additional, García Moreno, J.M., additional, Gastón, I., additional, Gómez Garre, M.P., additional, González Aloy, J., additional, González-Aramburu, I., additional, González Ardura, J., additional, González García, B., additional, González Palmás, M.J., additional, González Toledo, G.R., additional, Golpe Díaz, A., additional, Grau Solá, M., additional, Guardia, G., additional, Hernández-Vara, J., additional, Horta Barba, A., additional, Infante, J., additional, Jesús, S., additional, Kulisevsky, J., additional, Kurtis, M., additional, Labandeira, C., additional, Labrador, M.A., additional, Lacruz, F., additional, Lage Castro, M., additional, Legarda, I., additional, López Ariztegui, N., additional, López Díaz, L.M., additional, López Manzanares, L., additional, López Seoane, B., additional, Martí Andres, G., additional, Martí, M.J., additional, Martínez-Castrillo, J.C., additional, McAfee, D., additional, Meitín, M.T., additional, Menéndez González, M., additional, Méndez del Barrio, C., additional, Miranda Santiago, J., additional, Morales Casado, M.I., additional, Moreno Diéguez, A., additional, Nogueira, V., additional, Novo Amado, A., additional, Novo Ponte, S., additional, Ordás, C., additional, Pagonabarraga, J., additional, Pareés, I., additional, Pascual-Sedano, B., additional, Pastor, P., additional, Pérez Fuertes, A., additional, Pérez Noguera, R., additional, Planellas, Ll, additional, Pol Fuster, J., additional, Prats, M.A., additional, Prieto Jurczynska, C., additional, Puente, V., additional, Redondo Rafales, N., additional, Rodríguez Méndez, L., additional, Roldán, F., additional, Ruíz De Arcos, M., additional, Ruíz Martínez, J., additional, Sánchez Alonso, P., additional, Sánchez-Carpintero, M., additional, Sánchez Díez, G., additional, Sánchez Rodríguez, A., additional, Santacruz, P., additional, Segundo Rodríguez, J.C., additional, Seijo, M., additional, Serarols, A., additional, Sierra Peña, M., additional, Tartari, J.P., additional, Vargas, L., additional, Vázquez Gómez, R., additional, Villanueva, C., additional, Vives, B., additional, and Villar, M.D., additional
- Published
- 2019
- Full Text
- View/download PDF
34. The Persistence of the Black Colour in Magnetite‐Based Pigments in Prehispanic Ceramics of the Argentine North‐West
- Author
-
Puente, V., primary, Porto López, J. M., additional, Desimone, P. M., additional, and Botta, P. M., additional
- Published
- 2019
- Full Text
- View/download PDF
35. Factors determining TV soccer viewing: Does uncertainty of outcome really matter?
- Author
-
Levi Pérez, Puente, V., and Rodríguez, P.
- Abstract
The authors wish to express their gratitude for financial support from grant FC-15GRUPIN14-064
- Published
- 2017
36. Detection and imaging of quorum sensing in Pseudomonas aeruginosa biofilm communities by surface-enhanced resonance Raman scattering
- Author
-
Bodelón G., Montes-Garc¡a V., López-Puente V., Hill E.H., Hamon C., Sanz-Ortiz M.N., Rodal-Cedeira S., Costas C., Celiksoy S., Pérez-Juste I., Scarabelli L., La Porta A., Pérez-Juste J., Pastoriza-Santos I., and Liz-Marzán L.M.
- Subjects
biochemical phenomena, metabolism, and nutrition - Abstract
Most bacteria in nature exist as biofilms, which support intercellular signalling processes such as quorum sensing (QS), a cell-to-cell communication mechanism that allows bacteria to monitor and respond to cell density and changes in the environment. As QS and biofilms are involved in the ability of bacteria to cause disease, there is a need for the development of methods for the non-invasive analysis of QS in natural bacterial populations. Here, by using surface-enhanced resonance Raman scattering spectroscopy, we report rationally designed nanostructured plasmonic substrates for the in situ, label-free detection of a QS signalling metabolite in growing Pseudomonas aeruginosa biofilms and microcolonies. The in situ, non-invasive plasmonic imaging of QS in biofilms provides a powerful analytical approach for studying intercellular communication on the basis of secreted molecules as signals. ¸ Macmillan Publishers Limited. All rights reserved.
- Published
- 2016
37. COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation.
- Author
-
Santos García, D., Jesús, S., Aguilar, M., Planellas, L. L., García Caldentey, J., Caballol, N., Legarda, I., Hernández Vara, J., Cabo, I., López Manzanares, L., González Aramburu, I., Ávila Rivera, M. A., Catalán, M. J., López Díaz, L., Puente, V., García Moreno, J. M., Borrué, C., Solano Vila, B., Álvarez Sauco, M., and Vela, L.
- Subjects
PARKINSON'S disease ,DISEASE progression ,IMPULSE control disorders ,MENTAL depression ,DISEASE duration - Abstract
Background and purpose: In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well‐designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS‐2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015). Methods: This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants. Results: In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non‐Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non‐motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging). Conclusions: Parkinson's disease is a complex disorder and different non‐motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
38. Changes of spin axis and rate of the asteroid (99942) Apophis during the 2029 close encounter with Earth: A constrained model
- Author
-
Souchay, J., primary, Lhotka, C., additional, Heron, G., additional, Hervé, Y., additional, Puente, V., additional, and Folgueira Lopez, M., additional
- Published
- 2018
- Full Text
- View/download PDF
39. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry
- Author
-
Antonini, Angelo, primary, Poewe, Werner, additional, Chaudhuri, K. Ray, additional, Jech, Robert, additional, Pickut, Barbara, additional, Pirtošek, Zvezdan, additional, Szasz, Jozsef, additional, Valldeoriola, Francesc, additional, Winkler, Christian, additional, Bergmann, Lars, additional, Yegin, Ashley, additional, Onuk, Koray, additional, Barch, David, additional, Odin, Per, additional, Amalia, Ene, additional, Arnold, Guy, additional, Bajenaru, Ovidiu, additional, Bergmans, Bruno, additional, Bjornara, Kari Anne, additional, Blackie, Jeff, additional, Bode, Matthias, additional, Bourgeois, Paul, additional, Bohlhalter, Stephan, additional, Buraga, Ioan, additional, Burkhard, Pierre R., additional, Busson, Philippe, additional, Calopa, Matilde, additional, Clausen, Jesper, additional, Danielsen, Erik Hvid, additional, Defebvre, Luc, additional, Delvaux, Valerie, additional, Dethy, Sophie, additional, Dietrichs, Espen, additional, De Fabregues, Oriol, additional, Gerhard, Ransmayr, additional, Gusmaroli, Graziano, additional, Hahn, Kirsten, additional, Hauptmann, Björn, additional, Henriksen, Tove, additional, Hernandez-Vara, Jorge, additional, Jeanjean, A., additional, Kaiserova, Michaela, additional, Kassubek, Jan, additional, Kimber, Thomas, additional, Konitsiotis, Spyridon, additional, Krüger, Rejko, additional, Kulisevsky, Jaime, additional, Leenders, Jo, additional, Lundqvist, Christofer, additional, Ory Magne, F., additional, Marano, Pietro, additional, Milanov, Ivan, additional, Modugno, Nicola, additional, Misbahuddin, Anjum, additional, Nevrly, Martin, additional, Panayiotis, Zikos, additional, Pedersen, Kenn Freddy, additional, Pedersen, Stephen W., additional, Perju-Dumbrava, Lacramioara, additional, Ponsen, M.M., additional, Popescu, Bogdan O., additional, Rijntjes, Michel, additional, Puente, V., additional, Redecker, Christoph, additional, Schrader, Christoph, additional, Sensi, Mariachiara, additional, Simu, Mihaela, additional, Spanaki, Cleanthe, additional, Storch, Alexander, additional, Storstein, Anette, additional, Tomantschger, Volker, additional, van der Linden, Chris, additional, van Laar, T., additional, Viallet, F., additional, Witjas, Tatiana, additional, Wolz, Martin, additional, Zibetti, Maurizio, additional, and Van Zandijcke, Michel, additional
- Published
- 2017
- Full Text
- View/download PDF
40. Uncertainties estimation in surveying measurands: application to lengths, perimeters and areas
- Author
-
Covián, E, primary, Puente, V, additional, and Casero, M, additional
- Published
- 2017
- Full Text
- View/download PDF
41. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry
- Author
-
Buongiorno, M, Antonelli, F, Camara, A, Puente, V, de Fabregues-Nebot, O, Hernandez-Vara, J, Calopa, M, Pascual-Sedano, B, Campolongo, A, Valldeoriola, F, Tolosa, E, Kulisevsky, J, and Marti, MJ
- Subjects
Parkinson disease ,Levodopa/carbidopa intestinal gel ,Long-term treatment ,Non-motor symptoms ,Motor fluctuations - Abstract
Introduction: Continuous infusion of levodopa/carbidopa intestinal gel (LCIG) is an effective treatment for patients with advanced Parkinson Disease (PD) that cannot be further improved by oral therapy. Methods: We conducted an observational, prospective, and multicenter study to collect, in a large sample of PD treated with LCIG, long-term information about the outcome and safety of the treatment. The assessments were performed before LCIG, 1, 3, 6 months after, and ever since, every 6 months. Results: We studied 72 patients with a mean observation time of 22 months and a maximum of 48 months. During follow-up 28 patients discontinued the treatment, especially for lack of efficacy or adverse events related to the drug. We obtained a significant improvement of motor and non-motor fluctuations, mean off time and some non-motor symptoms. A significant increase in the percentage of time with dyskinesias was found in patients having less than 50% of the day with dyskinesias before LCIG. However, patients having already many dyskinesias before LCIG experienced a significant decrease of the troublesome dyskinesias, meaning that outcomes might be different depending on specific clinical characteristics. Adverse effects were in general minor but one case of intestinal perforation and one of abdominal cellulite were observed. Conclusions: We confirmed that LCIG is a very effective treatment option for advanced PD; however considering the findings that dyskinesia can increase and the potential for serious side effects, we suggest the necessity for development of guidelines that better define the profile of responders. (C) 2015 Elsevier Ltd. All rights reserved.
- Published
- 2015
42. The case for a scalable coherence protocol for complex on-chip cache hierarchies in many-core systems
- Author
-
Menezo L.G., Puente V., and Gregorio J.A.
- Published
- 2013
- Full Text
- View/download PDF
43. El uso de la lengua materna en interacciones orales en una lengua extranjera: Un estudio de casos
- Author
-
Puente V., Ruth N. and Chacón, Carmen Teresa
- Subjects
Mmediation ,Revistas ,First language ,Foreign language ,Scaffolding ,Artículos [Entre Lenguas] ,Mediaicón ,Interacciones orales ,Lengua extranjera ,Andamiaje ,Artes y Humanidades ,Oral interaction ,Centro de Investigaciones en Lenguas Extranjeras (CILE) ,Facultad de Humanidades y Educación ,Lengua materna - Abstract
El presente estudio consistió en analizar las interacciones orales en un aula de clases de inglés como lengua extranjera. Los propósitos eran conocer el rol de la lengua materna y su naturaleza en las interacciones orales en inglés, la concepción de los estudiantes en cuanto al uso del español durante estas interacciones y las situaciones en las que éste emergió. La investigación se fundamentó en un estudio de casos. Se usaron la observación participante, las notas de campo, las grabaciones orales y las de video y la entrevista semiestructurada como herramientas de recolección de la información. Se utilizó la triangulación de los datos durante el análisis. Los resultados indican que emplear la lengua materna durante las interacciones en la lengua extranjera tiene diferentes propósitos en diversas situaciones, sobre todo en el proceso de comunicación en el aula, pues la lengua materna sirve de andamio y mediadora del aprendizaje. Se concluye que existe la necesidad de replantear el uso de la lengua materna en la aula de lengua extranjera como una estrategia de comunicación y de mediación en situaciones de falta de comprensión o cuando la lengua materna sea necesaria y pertinente. Palabras claves: Interacciones orales, lengua materna, lengua extranjera, andamiaje, mediación This study analyzed the use and nature of Spanish (native language of the students) within the oral interactions in an English as a foreign language (EFL) classroom. It also analyzed the conceptions of students in relation to the use of their first language in this context, the purposes it was used for, and the situations in which it emerged. The research design used was a case study. The ethnographic tools used to obtain information were: participant-observation, field notes, oral and video recordings, and interviews. The information obtained was triangulated for the analysis. The results indicate that the use of the students’ first language in foreign language interactions has different purposes, depending on the situation, but it is mostly used for communication purposes in the classroom. The reason for this to happen in this study was that the first language worked as a scaffold during these interactions. The findings suggest that it is important to redefine and rethink the use of the students’ first language in an EFL classroom, both as a communication and as a mediation strategy, especially when misunderstandings occur and when the students’ first language is necessary, useful, and appropriate. * La Magister Ruth N. Puente V. es Profesora del Departamento de Idiomas, Universidad Experimental Francisco de Miranda, Falcón, Venezuela. * La Dra. Carmen T. Chacón, es Profesora Titular del Departamento de Idiomas Modernos, Núcleo “Pedro Rincón Gutiérrez”,Universidad de los Andes, Táchira, Venezuela. Key words: Oral interaction, first language, foreign language, scaffolding, mediation 43-62 ctchacon@cantv.net anual
- Published
- 2011
44. Permanent genetic resources added to Molecular Ecology Resources Database 1 April 2010-31 May 2010
- Author
-
Andree, K., Axtner, J., Bagley, M. J., Barlow, E. J., Beebee, T. J. C., Bennetzen, J. L., Bermingham, E., Boisselier-Dubayle, M. C., Bozarth, C. A., Brooks, C. P., Brown, R. P., Catanese, G., Cavers, S., Ceron-Souza, I., Chak, S. T. C., Chan, M. N., Charles-Dominique, P., Chen, C. Y., Chen, J. D., Chinchilla, L., Da Silva, D., Dafreville, S., Daunt, F., Delatte, H., Dorge, T., Duncan, N., Durand, Jean-Dominique, Duvernell, D., Estep, M., Fan, S., Fattahi, R., Villela, O. F., Fong, Y., Freville, H., Funes, V., Gallardo-Escarate, C., Ganeshaiah, K. N., Ghaffari, M. R., Girod, C., Gomez-Moliner, B. J., Gonzalez-Porter, G. P., Gosa, A., Govers, F., Guerin, F., Guindo, D., Hailer, F., Haye, P. A., Hoelmer, K. A., Hofmann, S., Hong, Y., Hu, C. Q., Huang, S. W., Humeau, L., Infante, C., Jackson, S. A., Jacobsen, E., Jowkar, A., Kafi, M., Kermani, M. J., Kim, H., Kim, K. S., Kim, M. Y., Knibb, W., Koita, O. A., Korpelainen, H., Lambourdiere, J., Lasso, E., Leblois, R., Lee, H., Lee, S. W., Leung, F. C. C., Leung, K. M. Y., Li, C. H., Li, Y., Lieckfeldt, D., Lizana, M., Loughry, W. J., Luo, P., Madeira, M. J., Mahmoodi, P., Maldonado, J. E., Mardi, M., Mendes, O., Miehe, G., Muth, P., Nacci, D., Kumar, L. N., Ng, W. C., Pailler, T., Parzies, H. K., Perez, L., Pfunder, M., Pietilaeinen, M., Pirseyedi, S. M., Porta, D., Porta, J., Porta, J. M., Quilici, S., Rakotoarivelo, F. P., Ramesha, B. T., Ravikanth, G., Riera, B., Risterucci, A. M., Roberts, D. A., Samadi, Sarah, Sarasola-Puente, V., Sarrazin, E., Sarthou, C., Schmidt, A., Segovia, N. I., Shen, K. N., Simiand, C., Bin Sman, M. H., Solhoy, T., Sommer, S., Sumangala, R. C., Taubert, R., Tejangkura, T., Telford, A., Testa, A., Tollon-Cordet, C., Tzeng, W. N., Shaanker, R. U., van der Lee, T. A. J., Van Mourik, T. A., Vasudeva, R., Wai, T. C., Wang, R. L., Welch, M. E., Weltzien, E., Whitehead, A., Woodard, A., Xia, J. J., Zeinolabedini, M., and Zhang, L.
- Abstract
This article documents the addition of 396 microsatellite marker loci to the Molecular Ecology Resources Database. Loci were developed for the following species: Anthocidaris crassispina, Aphis glycines, Argyrosomus regius, Astrocaryum sciophilum, Dasypus novemcinctus, Delomys sublineatus, Dermatemys mawii, Fundulus heteroclitus, Homalaspis plana, Jumellea rossii, Khaya senegalensis, Mugil cephalus, Neoceratitis cyanescens, Phalacrocorax aristotelis, Phytophthora infestans, Piper cordulatum, Pterocarpus indicus, Rana dalmatina, Rosa pulverulenta, Saxifraga oppositifolia, Scomber colias, Semecarpus kathalekanensis, Stichopus monotuberculatus, Striga hermonthica, Tarentola boettgeri and Thermophis baileyi. These loci were cross-tested on the following species: Aphis gossypii, Sooretamys angouya, Euryoryzomys russatus, Fundulus notatus, Fundulus olivaceus, Fundulus catenatus, Fundulus majalis, Jumellea fragrans, Jumellea triquetra Jumellea recta, Jumellea stenophylla, Liza richardsonii, Piper marginatum, Piper aequale, Piper darienensis, Piper dilatatum, Rana temporaria, Rana iberica, Rana pyrenaica, Semecarpus anacardium, Semecarpus auriculata, Semecarpus travancorica, Spondias acuminata, Holigarna grahamii, Holigarna beddomii, Mangifera indica, Anacardium occidentale, Tarentola delalandii, Tarentola caboverdianus and Thermophis zhaoermii.
- Published
- 2010
45. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life
- Author
-
Puente, V., De Fabregues, O., Oliveras, C., Ribera, G., Pont-Sunyer, C., Vivanco, R., Cucurella, G., Giralt, E., Delgado, T., Garcia, C., Seoane, A., and Campo, R.
- Published
- 2010
- Full Text
- View/download PDF
46. Rotational changes of the asteroid 99942 Apophis during the 2029 close encounter with Earth
- Author
-
Souchay, J., primary, Souami, D., additional, Lhotka, C., additional, Puente, V., additional, and Folgueira, M., additional
- Published
- 2014
- Full Text
- View/download PDF
47. Meningitis bacterianas en el cerdo
- Author
-
Ferri, E. F. R., Gutiérrez, C. B., Puente, V. A. De la, García, N., Navas, J., Paniagua, C., Río, M. L. Del, Monter, J. R., and García, J. N.
- Published
- 2000
48. Permanent Genetic Resources added to Molecular Ecology Resources Database 1 April 2010 – 31 May 2010: Isolation and characterization of microsatellite markers for the European shag, Phalacrocorax aristotelis.
- Author
-
Andree, K., Axtner, Jan, Bagley, M.J., Barlow, E.J., Beebee, T.J.C., Bennetzen, Jeffrey L., Bermingham, Eldredge, Boisselier-Dubayle, M.C., Bozart, Christine A., Brooks, Christopher P., Brown, R.P., Catanese, Gaetano, Cavers, S., Ceron-Souza, Ivania, Chak, Solomon T.C., Chan, M.N., Charles-Dominique, P., Chen, C.Y., Chen, J.D., Chinchilla, Leah, Da Silva, D., Dafreville, S., Daunt, F., Delatte, H., Dorge, T., Duncan, N., Durand, J.D., Duvernell, D., Estep, Matt, Fan, Sigang, Fattahi, R., Villela, Oscar Flores, Fong, Yokking, Freville, H., Funes, Victoria, Gallardo-Escarte, C., Ganeshaiah, K.N., Ghaffari, M.R., Girod, C., Gomez-Moliner, B.J., Gonzalez-Porter, Gracia P., Gosa, A., Govers, F., Guerin, F., Guindo, Diarah, Hailer, Frank, Haye, P.A., Hoelmer, Kim A., Hofmann, S., Hong, Yan, Hu, Chaoqun, Huang, S.W., Humeau, L., Infante, Carlos, Jackson, S.A., Jacobsen, E., Jowkar, A., Kafi, M., Kermani, J., Kim, Hyojoong, Kim, Kyung Seok, Knibb, W., Koita, Ousmane A., Korpelainen, H., Lambourdiere, J., Lasso, Eloisa, Leblois, R., Lee, Hang, Lee, Seunghwan, Leung, F.C.C., Leung, Kenneth M.Y., Li, Chunjong, Li, Y., Lieckfeldt, Dietmar, Lizana, M., Loughry, W.J., Luo, Peng, Madeira, M.J., Mahmoodi, P., Maldonado, Jesus E., Mardi, M., Mendes, O., Miehe, G., Muth, Peter, Nacci, D., Kumar, Naveen, Ng, Wai-Chuen, Pailler, T., Parzies, Heiko K., Perez, Laura, Pfunder, M., Pietilainen, M., Pirseyedi, S.M., Porta, D., Porta, J., Porta, J.M., Quilici, S., Rakotoarivelo, F.P., Ramesha, B.T., Ravikanth, G., Riera, B., Risterucci, A.M., Roberts, D.A., Samadi, S., Sarasola-Puente, V., Sarrazin, E., Sarthou, C., Schmidt, Anke, Segovia, N.I., Shen, K.N., Simiand, C., Sman, Muhammad Hidayat Bin, Solhoy, T., Sommer, Simone, Sumangala, R.C., Taubert, Ramona, Tejangkura, T., Telford, A., Testa, A., Tollon-Cordet, C., Tzeng, W.N., Uma-Shaanker, R., Van Der Lee, T.A.J., Van Mourik, Thomas A., Vasudeva, R., Wai, T.C., Wang, R.L., Welch, Mark E., Weltzein, Eva, Whitehead, A., Woodard, Anastasia, Xia, Jianjun, Zeinolabedini, M., Zhang, Lvping, Andree, K., Axtner, Jan, Bagley, M.J., Barlow, E.J., Beebee, T.J.C., Bennetzen, Jeffrey L., Bermingham, Eldredge, Boisselier-Dubayle, M.C., Bozart, Christine A., Brooks, Christopher P., Brown, R.P., Catanese, Gaetano, Cavers, S., Ceron-Souza, Ivania, Chak, Solomon T.C., Chan, M.N., Charles-Dominique, P., Chen, C.Y., Chen, J.D., Chinchilla, Leah, Da Silva, D., Dafreville, S., Daunt, F., Delatte, H., Dorge, T., Duncan, N., Durand, J.D., Duvernell, D., Estep, Matt, Fan, Sigang, Fattahi, R., Villela, Oscar Flores, Fong, Yokking, Freville, H., Funes, Victoria, Gallardo-Escarte, C., Ganeshaiah, K.N., Ghaffari, M.R., Girod, C., Gomez-Moliner, B.J., Gonzalez-Porter, Gracia P., Gosa, A., Govers, F., Guerin, F., Guindo, Diarah, Hailer, Frank, Haye, P.A., Hoelmer, Kim A., Hofmann, S., Hong, Yan, Hu, Chaoqun, Huang, S.W., Humeau, L., Infante, Carlos, Jackson, S.A., Jacobsen, E., Jowkar, A., Kafi, M., Kermani, J., Kim, Hyojoong, Kim, Kyung Seok, Knibb, W., Koita, Ousmane A., Korpelainen, H., Lambourdiere, J., Lasso, Eloisa, Leblois, R., Lee, Hang, Lee, Seunghwan, Leung, F.C.C., Leung, Kenneth M.Y., Li, Chunjong, Li, Y., Lieckfeldt, Dietmar, Lizana, M., Loughry, W.J., Luo, Peng, Madeira, M.J., Mahmoodi, P., Maldonado, Jesus E., Mardi, M., Mendes, O., Miehe, G., Muth, Peter, Nacci, D., Kumar, Naveen, Ng, Wai-Chuen, Pailler, T., Parzies, Heiko K., Perez, Laura, Pfunder, M., Pietilainen, M., Pirseyedi, S.M., Porta, D., Porta, J., Porta, J.M., Quilici, S., Rakotoarivelo, F.P., Ramesha, B.T., Ravikanth, G., Riera, B., Risterucci, A.M., Roberts, D.A., Samadi, S., Sarasola-Puente, V., Sarrazin, E., Sarthou, C., Schmidt, Anke, Segovia, N.I., Shen, K.N., Simiand, C., Sman, Muhammad Hidayat Bin, Solhoy, T., Sommer, Simone, Sumangala, R.C., Taubert, Ramona, Tejangkura, T., Telford, A., Testa, A., Tollon-Cordet, C., Tzeng, W.N., Uma-Shaanker, R., Van Der Lee, T.A.J., Van Mourik, Thomas A., Vasudeva, R., Wai, T.C., Wang, R.L., Welch, Mark E., Weltzein, Eva, Whitehead, A., Woodard, Anastasia, Xia, Jianjun, Zeinolabedini, M., and Zhang, Lvping
- Abstract
This article documents the addition of 396 microsatellite marker loci to the Molecular Ecology Resources Database. Loci were developed for the following species: Anthocidaris crassispina, Aphis glycines, Argyrosomus regius, Astrocaryum sciophilum, Dasypus novemcinctus, Delomys sublineatus, Dermatemys mawii, Fundulus heteroclitus, Homalaspis plana, Jumellea rossii, Khaya senegalensis, Mugil cephalus, Neoceratitis cyanescens, Phalacrocorax aristotelis, Phytophthora infestans, Piper cordulatum, Pterocarpus indicus, Rana dalmatina, Rosa pulverulenta, Saxifraga oppositifolia, Scomber colias, Semecarpus kathalekanensis, Stichopus monotuberculatus, Striga hermonthica, Tarentola boettgeri and Thermophis baileyi. These loci were cross-tested on the following species: Aphis gossypii, Sooretamys angouya, Euryoryzomys russatus, Fundulus notatus, Fundulus olivaceus, Fundulus catenatus, Fundulus majalis, Jumellea fragrans, Jumellea triquetra Jumellea recta, Jumellea stenophylla, Liza richardsonii, Piper marginatum, Piper aequale, Piper darienensis, Piper dilatatum, Rana temporaria, Rana iberica, Rana pyrenaica, Semecarpus anacardium, Semecarpus auriculata, Semecarpus travancorica, Spondias acuminata, Holigarna grahamii, Holigarna beddomii, Mangifera indica, Anacardium occidentale, Tarentola delalandii, Tarentola caboverdianus and Thermophis zhaoermii.
- Published
- 2010
49. Immunet: Dependable Routing for Interconnection Networks with Arbitrary Topology
- Author
-
Puente, V., primary, Gregorio, J.A., additional, Vallejo, F., additional, and Beivide, R., additional
- Published
- 2008
- Full Text
- View/download PDF
50. Situación actual de la farmacocinética clínica en la red de hospitales públicos de Castilla y León
- Author
-
Puente, V., primary, Almendros, R., additional, and Prada, J., additional
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.